# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-065765
Filing Date
2025-05-07
Accepted
2025-05-07 16:30:39
Documents
86
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | inva-20250331.htm iXBRL | 10-Q | 2797907
2 | EX-31.1 | inva-ex31_1.htm | EX-31.1 | 14340
3 | EX-31.2 | inva-ex31_2.htm | EX-31.2 | 14341
4 | EX-32 | inva-ex32.htm | EX-32 | 22776
| Complete submission text file | 0000950170-25-065765.txt |  | 13441109

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | inva-20250331.xsd | EX-101.SCH | 1857768
89 | EXTRACTED XBRL INSTANCE DOCUMENT | inva-20250331_htm.xml | XML | 2864250

Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filer) CIK: 0001080014 (see all company filings)

EIN.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30319 | Film No.: 25921947
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)